Michael R Cook, MD
Assistant Professor of Clinical Medicine (Hematology-Oncology)
Department: Medicine
Contact information
Penn Presbyterian Medical Center
51 N 39th St, 1st Floor PAC building
Philadelphia, PA 19104
51 N 39th St, 1st Floor PAC building
Philadelphia, PA 19104
Office: 267-588-2569
Education:
BS (Biology: Vertebrate Physiology; Minor Psychology and Neuroscience)
Pennsylvania State University, 2013.
MD (Medicine)
Lewis Katz School of Medicine at Temple University, 2017.
Permanent linkBS (Biology: Vertebrate Physiology; Minor Psychology and Neuroscience)
Pennsylvania State University, 2013.
MD (Medicine)
Lewis Katz School of Medicine at Temple University, 2017.
Description of Clinical Expertise
Indolent B-cell Lymphoma (Follicular Lymphoma, Marginal Zone Lymphoma, Chronic lymphocytic leukemia/small lymphocytic lymphoma, lymphoplasmacytic lymphoma)Mantle Cell Lymphoma
Diffuse Large B-cell Lymphoma
Primary Mediastinal B-cell Lymphoma
Selected Publications
Nikita K. Dave, Veronica Carvajal, Alex C. Watts, Jordan S. Carter, Michael Cook, Colin Thomas, Donald E. Tsai, Stephen J. Schuster, James N. Gerson, Stefan K. Barta, Jakub Svoboda, Elise A. Chong, Wei-Ting Hwang, Daniel J. Landsburg, Sunita D. Nasta : Outcomes at a Single Institution with MTR Induction and Consolidation in the Management of Primary CNS Lymphoma. Blood Neoplasia April 2025 Notes: E-published on April 16, 2025.Cook, M.R. Williams, L. Kolm, P. Dunleavy, K. : Improved Survival Outcomes for Intensive versus Standard Chemoimmunotherapy in Primary Mediastinal B-cell Lymphoma: A Meta-Analysis of 4068 Patients. Haematologica 109(3), March 2024.
Cook, M.R, Shouval, R. Perales, M, et al. : Real-World Evidence in the United States (US) of the Impact of Bridging Therapy Prior to Axicabtagene Ciloleucel (Axi-Cel) for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL). ASH Annual Conference 2023 Dec 2023 Notes: Oral Presentation.
Cook, M.R. Dorris, SC. Makambi, K. Luo, Y. Munshi, P. Donato, M. Rowley, S. Saad, A. Goy, A. Dunleavy, K. Ali, A. : Toxicity and Efficacy of Chimeric Antigen Receptor (CAR) T-cell Therapy in Primary and Secondary CNS Lymphoma: A Meta-Analysis of 128 Patients. Blood Adv 7(1): 32-39, Jan 2023.
Shah NJ, Cook MR, Wu T, Lev-Ari SL, Blackburn MB, Serzan MT, Alaoui A, Atkins, MB. : Association Between Immune Checkpoint Inhibitors, Corticosteroids, Immunosuppressive Agents and Opportunistic Infections. Journal of the National Comprehensive Cancer Network 20(7), July 2022.
Shah NJ, Cook MR, Wu T, Lev-Ari SL, Blackburn MB, Serzan MT, Alaoui A, Atkins, MB. : The Risk of Opportunistic Infections and the Role of Antibiotic Prophylaxis in Patients on Checkpoint Inhibitors Requiring Steroids J Natl Compr Canc Netw 20(7): 800-807.e1. Jul 2022.
Cook, M.R. Dunleavy, K. : Targeting the Tumor Microenvironment in Lymphomas: Emerging Biological Insights and Therapeutic strategies. Current Oncology Reports 24: 1121-1131, Apr 2022.
Zhang D, Shah NJ, Cook MR, Blackburn M, Serzan MT, Advani S, Potosky AL, Atkins MB, Braithwaite D. : Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis. Cancers (Basel) 13(23): 6109, Dec 2021.
Cook, M., Dykes, K., White, K., Desale, S., Agrawal, R., Fernandez, S., Huang, X., Cobb, N., Lai, C.: Clinical Outcomes in Patients with Hematologic Malignancy (HM) and COVID-19. Clinical Lymphoma, Myeloma & Leukemia Dec 2021.
Cook, M.R. Karp, J.E. Lai, C. : The Spectrum of Genetic Mutations in Myelodysplastic Syndrome: Should We Update Prognostication? EJHaem 3(1): 301-313, Nov 2021.